Literature DB >> 14597453

Dermatofibrosarcoma protuberans: reappraisal of wide local excision and impact of inadequate initial treatment.

Vijay P Khatri1, Joseph M Galante, Richard J Bold, Philip D Schneider, Rajendra Ramsamooj, James E Goodnight.   

Abstract

BACKGROUND: The extent of local invasion in dermatofibrosarcoma protuberans (DFSP) is often clinically difficult to appreciate, and this leads to inadequate resections. We examined the effect of inadequate initial treatment and the efficacy of wide resection.
METHODS: We performed a retrospective analysis of the records of 35 patients with DFSP treated at our institution (1985 and 2001). Data were analyzed with Wilcoxon's ranked sum test and Fisher's exact test.
RESULTS: Of the 24 patients eligible for analysis, 11 had definitive wide resection after diagnostic excisions elsewhere (primary group), and 13 had recurrent tumors after previous surgical treatment elsewhere (recurrent group). Twenty-three patients were treated with wide resection only, and adjuvant radiation was administered to one patient who had a fibrosarcoma. At a median follow-up of 54 months, patients definitively treated at our institution had a 100% local recurrence-free survival. In comparison to the primary group, recurrent DFSPs were significantly larger and deeper and occurred in the head and neck region. Five cases had bone involvement, and of these, 80% occurred in the recurrent group.
CONCLUSIONS: Inadequate initial treatment results in larger, deeper recurrent lesions, but these can be managed by appropriate wide excision. Wide resection of DFSP (whether recurrent or primary) with negative histological margins predicts a superior local recurrence-free survival.

Entities:  

Mesh:

Year:  2003        PMID: 14597453     DOI: 10.1245/aso.2003.03.581

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  18 in total

1.  [Painless, gradually accumulating induration of the preauricular skin].

Authors:  M C Jäckel; S Rapprich; U W Wahlmann
Journal:  HNO       Date:  2007-05       Impact factor: 1.284

Review 2.  Targeted therapy for dermatofibrosarcoma protuberans.

Authors:  Thomas A Abrams; Scott M Schuetze
Journal:  Curr Oncol Rep       Date:  2006-07       Impact factor: 5.075

3.  Dermatofibrosarcoma protuberans: a case report and review of the literature.

Authors:  D Paramythiotis; G Stavrou; D Panagiotou; G Petrakis; A Michalopoulos
Journal:  Hippokratia       Date:  2016 Jan-Mar       Impact factor: 0.471

4.  Dermatofibrosarcoma Protuberans of the Neck: A Brief Review of the Literature.

Authors:  Sevim Aslan Felek; Mustafa İbas; Songul Dursun; Aylin Okcu Heper
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2018-03-22

5.  Dermatofibrosarcoma protuberans (DFSP): predictors of recurrence and the use of systemic therapy.

Authors:  Ryan C Fields; Meera Hameed; Li-Xuan Qin; Nicole Moraco; Xiaoyu Jia; Robert G Maki; Samuel Singer; Murray F Brennan
Journal:  Ann Surg Oncol       Date:  2010-09-16       Impact factor: 5.344

6.  Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials.

Authors:  Piotr Rutkowski; Martine Van Glabbeke; Cathryn J Rankin; Wlodzimierz Ruka; Brian P Rubin; Maria Debiec-Rychter; Alexander Lazar; Hans Gelderblom; Raf Sciot; Dolores Lopez-Terrada; Peter Hohenberger; Allan T van Oosterom; Scott M Schuetze
Journal:  J Clin Oncol       Date:  2010-03-01       Impact factor: 44.544

7.  Dermatofibrosarcoma protuberans in a 10-year-old child.

Authors:  Uwe Wollina
Journal:  J Dermatol Case Rep       Date:  2013-12-30

Review 8.  Current treatment options in dermatofibrosarcoma protuberans.

Authors:  Doreen Lemm; L-O Mügge; T Mentzel; K Höffken
Journal:  J Cancer Res Clin Oncol       Date:  2009-02-10       Impact factor: 4.553

Review 9.  Imatinib in the treatment of solid tumours.

Authors:  Florence Duffaud; Axel Le Cesne
Journal:  Target Oncol       Date:  2009-01-27       Impact factor: 4.493

Review 10.  [Dermatofibrosarcoma protuberans].

Authors:  S Ugurel
Journal:  Hautarzt       Date:  2008-11       Impact factor: 0.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.